Solvonis Therapeutics plc (LSE:SVNS) has raised £1.25 million through a direct subscription with institutional and strategic investors, aiming to accelerate progress across its central nervous system (CNS) disorder programs. The new capital will fund the company’s expanded three-pillar strategy focused on addiction, psychiatry, and neurology.
This investment will support the advancement of both clinical and pre-clinical initiatives, broaden CNS drug-discovery activities, and enhance R&D infrastructure. The financing marks a key milestone for Solvonis, strengthening its position in the biopharmaceutical sector and providing the foundation for continued scientific and clinical development.
About Solvonis Therapeutics
Solvonis Therapeutics is a London-based biopharmaceutical company developing innovative small-molecule therapies for high-burden CNS disorders. Listed on the main market of the London Stock Exchange, the company is building a pipeline spanning addiction, psychiatry, and neurology. Its lead programs target conditions such as Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD), reflecting its commitment to addressing significant unmet medical needs.
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.
Some portions of this content may have been generated or assisted by artificial intelligence (AI) tools and been reviewed for accuracy and quality by our editorial team.
Leave a Reply